SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.61-0.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (9026)9/2/2003 4:19:55 PM
From: Biomaven  Read Replies (1) of 52153
 
The optimum time for drug licensing

But note that the numbers they quote as "typical" deals are lower (at least for late-stage products) than those you would expect to see now. Of course their point still holds if the increase has been across the board from early-stage to late.

Biotechs are much less willing to do low-level early stage deals than they used to be. The early-stage deals you see now are either from desperate biotechs trying to keep the doors open, or have numbers more typical of later-stage deals (e.g., epo D from KOSN).

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News